Lete-Cel for Synovial Sarcoma

Recruiting in Palo Alto (17 mi)

+37 other locations

Age: Any Age

Sex: Any

Travel: May Be Covered

Time Reimbursement: Varies

Trial Phase: Phase 2

Waitlist Available

Sponsor: Adaptimmune

No Placebo Group

Prior Safety Data

Trial Summary

What is the purpose of this trial?

This trial will evaluate safety and efficacy of human engineered T-cell therapies, in participants with advanced tumors. This trial is a sub study of the Master study NCT03967223.

Research Team

Eligibility Criteria

This trial is for people with advanced synovial sarcoma or myxoid/round cell liposarcoma that have already been treated. Participants must have a specific immune system marker called HLA-A2 and their tumors need to test positive for NY-ESO-1.

Inclusion Criteria

My disease has a specific genetic change according to the study's requirements.

I am healthy enough for a procedure to collect white blood cells and have good veins for it.

My heart pumps well and I don't have fluid around it.

See 16 more

Exclusion Criteria

I have another cancer that is not fully in remission.

My cancer has spread to my brain or spinal cord.

I have received a NY-ESO-1 vaccine or antibody treatment.

See 12 more

Treatment Details

Interventions

Lete-Cel (CAR T-cell Therapy)

Trial OverviewThe study is testing Letetresgene autoleucel, an experimental T-cell therapy designed to target cancer cells in patients with certain advanced tumors. It's part of a larger research project on engineered T-cell therapies.

Participant Groups

1Treatment groups

Experimental Treatment

Group I: Letetresgene autoleucelExperimental Treatment1 Intervention